CLE-HM29A-100μg / 询价
CLE-HM29A-500μg / 询价
CLE-HM29A-500μgx2 / 询价
- 客服电话
- 技术支持
Human CLEC9A Protein
Recombinant Human CLEC9A Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Lys57-Val241 [Accession | Q6UXN8].
The protein has a predicted MW of 48.5 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human CLEC9A on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human CLEC9A is greater than 95% as determined by SEC-HPLC.
Immobilized Human CLEC9A, hFc Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Anti-CLEC9A Antibody, hFc Tag with the EC50 of 5.9ng/ml determined by ELISA.
CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.
CD370; CLEC9A; 9830005G06Rik; DNGR-1; HEEE9341; UNQ9341
(1) Ramos MI, Teunissen MB, Helder B, Aarrass S, de Hair MJ, van Kuijk AW, Gerlag DM, Tak PP, Lebre MC. Reduced CLEC9A expression in synovial tissue of psoriatic arthritis patients after adalimumab therapy. Rheumatology (Oxford). 2016 Sep;55(9):1575-84. doi: 10.1093/rheumatology/kew204. Epub 2016 May 13. PMID: 27179104.
